Inclusion Criteria:

          -  Documented informed consent of participant and/or legally authorized representative

          -  Agreement to allow the use of archival tissue from diagnostic tumor biopsies will be
             retrieved and submitted post-enrollment

               -  If unavailable, exceptions may be granted with study principal investigator (PI)
                  approval.

          -  Eastern Cooperative Oncology Group (ECOG) status =< 2

          -  Histologically confirmed mature peripheral T-cell or natural killer (NK)-cell lymphoma
             per World Health Organization (WHO) classification, including:

               -  Anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma (ALCL)
                  with international protein index (IPI) of 2 or higher (must have bulky [defined
                  as mass >= 10 cm] stage II, or stage III-IV disease)

               -  ALK-negative ALCL

                    -  NOTE: Per amendment dated 05-10-19, ALCL will no longer be eligible except
                       for Canada.

               -  PTCL-not otherwise specified (NOS)

               -  Angioimmunoblastic T-cell lymphoma (AITL)

               -  Adult T-cell lymphoma/leukemia (ATLL)

               -  Enteropathy-associated T-cell lymphoma (EATL)

               -  Hepatosplenic T-cell lymphoma

          -  CD30-positivity (e.g. at least 1%) by immunohistochemistry confirmed by
             hematopathology review at the participating institution

          -  Measurable disease of at least 1.5 cm on computed tomography (CT) or positron emission
             tomography (PET)-CT scan

          -  Absolute neutrophil count (ANC) >= 1,000/mm^3

               -  Exception: unless documented bone marrow involvement by lymphoma

          -  Platelets >= 50,000/mm^3

               -  Exception: unless documented bone marrow involvement by lymphoma

          -  Total serum bilirubin =< 1.5 x upper limit of normal (ULN) OR if hepatic involvement
             by lymphoma: =< 3 x ULN for Gilbert's disease or documented hepatic involvement by
             lymphoma

          -  Aspartate aminotransferase (AST) =< 2 x ULN OR if hepatic involvement by lymphoma: AST
             =< 5 x ULN

          -  Alanine aminotransferase (ALT) =< 2 x ULN OR if hepatic involvement by lymphoma: ALT
             =< 5 x ULN

          -  Creatinine clearance of >= 60 mL/min per the Cockcroft-Gault formula

          -  Left ventricular ejection fraction (LVEF) >= 45%

          -  Women of childbearing potential (WOCBP): negative urine or serum pregnancy test; if
             the urine test is positive or cannot be confirmed as negative, a serum pregnancy test
             will be required

          -  Agreement by WOCBP and males of childbearing potential to use an effective method of
             birth control or abstain from heterosexual activity for the course of the study
             through at least 6 months after the last dose of protocol therapy; childbearing
             potential defined as not being surgically sterilized (men and women) or have not been
             free from menses for > 1 year (women only)

        Exclusion Criteria:

          -  Prior treatment of PTCL with systemic anti-lymphoma therapies, investigational agents,
             radiation

               -  Exception: May have received 1 cycle of CHOP-like therapy (e.g. CHOP, CHOEP,
                  EPOCH) or 1 cycle of CHP-BV; these participants must initiate day 1 cycle 1 of
                  study therapy (CHEP-BV) no less than 19 days from prior CHOP-like or CHP-BV
                  therapy; Patients who received 1 cycle of CHOP-like or 1 cycle of CHP-BV therapy
                  prior to initiating induction with CHEP-BV are allowed to receive only 5 cycles
                  of CHEP-BV instead of 6 cycles, per investigator's discretion

          -  History of another primary invasive cancer, hematologic malignancy, or myelodysplastic
             syndrome that has not been in remission for at least 3 years.

               -  Exceptions: Non-melanoma skin cancer and in situ cervical cancer

          -  Symptomatic cardiac disease (including symptomatic ventricular dysfunction,
             symptomatic coronary artery disease, and symptomatic arrhythmias), cerebrovascular
             event/stroke or myocardial infarction within the past 6 months

          -  Central nervous system involvement by lymphoma, including leptomeningeal involvement

          -  History of progressive multifocal leukoencephalopathy (PML)

          -  Active >= grade 3 viral, bacterial, or fungal infection within 2 weeks prior to day 1
             of protocol therapy

          -  Any known human immunodeficiency virus (HIV) infection, hepatitis B surface
             antigen-positive status, or known or suspected active hepatitis C infection

          -  Baseline peripheral neuropathy >= grade 2 or patients with the demyelinating form of
             Charcot-Marie-Tooth syndrome

          -  Known severe hypersensitivity to any study related agent excipient(s)

          -  Females only: pregnant or breastfeeding

          -  Any other condition that would, in the investigator's judgement, contraindicate the
             patient's participation in the clinical study

          -  Prospective participants who, in the opinion of the investigator, may not be able to
             comply with all study procedures (including compliance issues related to
             feasibility/logistics)